PMID- 21978091
OWN - NLM
STAT- MEDLINE
DCOM- 20120607
LR  - 20220321
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 19
IP  - 3
DP  - 2012 Mar
TI  - Combination of transcranial sonography, olfactory testing, and MIBG myocardial 
      scintigraphy as a diagnostic indicator for Parkinson's disease.
PG  - 411-6
LID - 10.1111/j.1468-1331.2011.03533.x [doi]
AB  - BACKGROUND: Appropriate diagnostic biomarkers are useful for improving speed and 
      accuracy of a diagnosis. Substantia nigra (SN) hyperechogenicity visualized by 
      transcranial sonography (TCS), olfactory dysfunction, and the reduced uptake of 
      (123) I-metaiodobenzylguanidine (MIBG) in myocardial scintigraphy have been 
      suggested as potential biomarkers for the identification of Parkinson's disease 
      (PD). OBJECTIVES: To evaluate the diagnostic potential of these tests and to 
      determine whether combining them increases their diagnostic power. METHODS:   
      Subjects were 44 patients with clinically diagnosed PD and 36 healthy controls. 
      TCS of the SN, the odor stick identification test for Japanese (OSIT-J), and MIBG 
      myocardial scintigraphy were conducted. RESULTS: Eleven patients with PD (25%) 
      and four controls (11%) were excluded because of an insufficient acoustic 
      temporal bone window in the TCS. Thus, 33 patients with PD and 32 healthy 
      controls were finally included. The diagnostic sensitivity of TCS, OSIT-J, and 
      MIBG myocardial scintigraphy was 78.8%, 84.8%, and 60.6%, respectively. The 
      specificity of TCS and OSIT-J was 93.8% and 78.1%, respectively. The combination 
      of TCS of the SN and OSIT-J substantially increased the sensitivity to a 
      sufficient level for discriminating patients with PD from controls. CONCLUSION: 
       TCS of the SN and olfactory testing play complementary roles in increasing 
      diagnostic power in PD. As both tests are easy to perform, noninvasive, and 
      inexpensive, the combination of TCS of the SN and olfactory testing may 
      contribute to early and accurate diagnosis of PD.
CI  - (c) 2011 The Author(s). European Journal of Neurology (c) 2011 EFNS.
FAU - Izawa, M O
AU  - Izawa MO
AD  - Department of Neurology, Wakayama Medical University, Wakayama, Japan. 
      kumakawaii@leto.eonet.ne.jp
FAU - Miwa, H
AU  - Miwa H
FAU - Kajimoto, Y
AU  - Kajimoto Y
FAU - Kondo, T
AU  - Kondo T
LA  - eng
PT  - Journal Article
DEP - 20111007
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Radiopharmaceuticals)
RN  - 35MRW7B4AD (3-Iodobenzylguanidine)
SB  - IM
MH  - *3-Iodobenzylguanidine
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Perfusion Imaging
MH  - Olfaction Disorders/diagnosis/etiology
MH  - Parkinson Disease/complications/*diagnosis
MH  - *Radiopharmaceuticals
MH  - Sensitivity and Specificity
MH  - *Ultrasonography, Doppler, Transcranial
EDAT- 2011/10/08 06:00
MHDA- 2012/06/08 06:00
CRDT- 2011/10/08 06:00
PHST- 2011/10/08 06:00 [entrez]
PHST- 2011/10/08 06:00 [pubmed]
PHST- 2012/06/08 06:00 [medline]
AID - 10.1111/j.1468-1331.2011.03533.x [doi]
PST - ppublish
SO  - Eur J Neurol. 2012 Mar;19(3):411-6. doi: 10.1111/j.1468-1331.2011.03533.x. Epub 
      2011 Oct 7.